诺和诺德的减肥药Wegovy近日获美国FDA批准新用途，可用于治疗代谢功能障碍相关脂肪性肝炎（MASH），消息推动公司股价一度上涨5%。这一突 破使诺和诺德在激烈的GLP-1药物市场竞争中，针对MASH领域抢占先发优势，以扭转年初以来的市值颓势。 诺和诺德的重磅药物Wegovy在一场关键的赛跑中击败竞争对手，其股价应声上涨。 据媒体18日报道，美国食品药品监督管理局（FDA）于上周五晚间批准了Wegovy的新用途。这一消息直接推动诺和诺德股价一度上涨高达5%，现已 回落至4.08%。 "在MASH领域获得批准，可能有助于改变诺和诺德在经历了一个较为艰难的开年后所面临的势头。" FDA批准Wegovy新用途——"肝病" Wegovy所属的GLP-1类药物因其显著的减重效果而广为人知，并由此催生了一个蓬勃发展的市场。将Wegovy的应用范围从单一的减肥领域拓展出去， 无疑将增强其市场竞争力。此次批准为诺和诺德在针对MASH（代谢功能障碍相关脂肪性肝炎）的治疗领域，赢得了对其主要竞争对手礼来的宝贵先发 优势。 对于诺和诺德而言，拓展新用途是支撑其旗舰产品需求的关键一步。 目前，Wegovy的销售增长正受到来自更便宜 ...

智通财经APP获悉，周一，医疗保健及医药板块走高，截至发稿，联合健康(UNH.US)涨超2.5%，此前 巴菲特披露持有该股；Molina Health(MOH.US)涨超2%，信诺(CI.US)涨超1.5%，诺和诺德(NVO.US)涨 超4.7%，强生(JNJ.US)涨0.22%，礼来(LLY.US)涨0.4%。 ...

Market Dynamics - Novo Nordisk is aiming to regain market share from Eli Lilly in the GLP-1 market [2][10] - The obesity market is projected to reach $95 billion by 2030 [11] - Novo Nordisk is competing with compounders who offer lower-priced alternatives [4][5] Strategic Moves - Novo Nordisk is launching a cash pay version of Ozempic and expanding partnerships to increase drug accessibility [3][9] - Novo Nordisk is lowering the price of Ozempic for cash-paying patients [3][4] - Novo Nordisk already launched cash pay at cheaper Wegovy back in March for $500 per month [8] Financial Implications - The cost of Ozempic for cash-paying patients is $500 per month at the maximum dose of 2 milligrams per injection, which is $65 per milligram [4] - Compounders are offering alternatives at prices like $119.90 [5]

Group 1 - Novo Nordisk shares rose by 5.9% following FDA approval for the weight loss drug Wegovy to be used in liver disease treatment [1] - Terawulf shares increased by 12.6% after Google announced an increase in its stake in Terawulf from approximately 8% to 14% [1] - Soho House shares surged by 16.2% as MCR Hotels' lead investor plans to take the company private at approximately $9 per share [1] - iQIYI shares jumped by 17.1% with the recent launch of the new series "生万物," achieving significant viewership on both TV and online platforms [1]

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious disease of the liver. https://t.co/rwkXWWWDUo ...

Market Dynamics & Drug Approvals - Novo Nordisk's weight loss drug VGOI receives FDA approval for treating a serious metabolic liver disease [1] - Novo Nordisk to sell Ozmpic directly to consumers through its Novocare platform at $4.99 per month for out-of-pocket payers [2] - Ozmpic and WGOI share the same active ingredient, but Ozmpic is approved for diabetes, while WGOI is for weight loss [3] Competitive Landscape & Pricing Strategies - Novo Nordisk aims to combat compounders selling knockoff versions of semaglutide, which impacted the company's full-year sales forecast [5] - Legitimate versions of weight loss drugs from Eli Lilly and Novo Nordisk are priced around $500, competing with compounded versions available for $200-$300 per month [6] - Eli Lilly increased the price of Mounjaro in the UK to equalize prices with the US and other countries [8] Future Outlook & Market Evolution - The market is evolving with oral versions and new companies entering, but the oral drug data from Lily disappointed investors [10][11] - Medicare will soon negotiate the price of Ozmpic, potentially affecting WGOI and spilling into the commercial market, which could lower prices [13] - Manufacturing costs pose a significant barrier to entry for new competitors against established players like Novo Nordisk [14]

NVO suffered its worst drop on record less than a month ago, but is pointed higher todayPharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the treatment of liver disease in the U.S. Today's pop comes just weeks after the company slashed its 2025 profit outlook and appointed a new CEO, resulting in a 21.8% bear gap on July 29, its worst drop on record. NVO is off 39% i ...

21:15 中概股盘前表现活跃，迅雷大涨超23%，爱奇艺涨17%，斗鱼涨超9%。 21:30 美股开盘丨美股三大指数小幅低开中概股普涨 道指跌0.14%，标普500指数跌0.09%，纳指跌0.06%。中概股普涨，纳斯达克中国金龙指数涨1.2%，迅 雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%，其新药获批后降低Ozempic价格。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 道琼斯工业指数 | 44883.39 | -62.73 | -0.14% | | 纳斯达克指数 | 21609.23 c | -13.75 | -0.06% | | 标普500 | 6443.85 | -5.95 | -0.09% | 16:34 联合健康美股盘前涨超3%。 （文章来源：第一财经） 21:06 诺和诺德美股盘前涨超5%，美国FDA批准将减肥药Wegovy用于肝病治疗。 ...

每经AI快讯，8月18日，美股三大指数开盘集体下跌，道琼斯指数跌0.14%，标普500指数跌0.11%，纳 斯达克综合指数跌0.05%。中概股普涨，迅雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%。 ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. https://t.co/4oygIL7lub ...